Ankabala Vera Therapeutics ( NASDAQ: VERA ) stock closed 15% higher Monday in the wake of positive long-term data from a Phase 2b study of its drug atacicept in the treatment of IgAN, a type of kidney disease. Vera ( VERA ) said 96-week results.
Back to Health Page
